SVF
Level C· Early Human ResearchProspective Study

HDAC1-overexpressing dermal papilla cell-derived extracellular vesicles modulate p53 and Wnt/β-catenin signaling to rescue hair follicle regeneration in androgenetic alopecia.

Sun Y., Jia L., Xiong J., Zhu Y., Zhang H., Yang F.

Prospective Study on Scar, Hair Loss, published in Biomaterials (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Biomaterials (2026)
Country
Netherlands
Reported sample size
—
PMID
41506142
DOI
10.1016/j.biomaterials.2025.123969

Abstract (original English)

Androgenetic alopecia (AGA), a prevalent non-scarring alopecia, poses significant therapeutic limitations due to the restricted efficacy and potential side effects of current interventions. Cell-derived nanovesicles (CNVs), noted for their biocompatibility and efficient delivery capacity, have been investigated as promising therapeutic carriers. Comparative studies of CNVs sourced from HaCat cells, adipose-derived stem cells, and dermal papilla cells demonstrated that those derived from dermal papilla cells exhibit enhanced cellular internalization and targeting specificity. Proteomic analyses revealed a notable suppression of Histone Deacetylase 1 (HDAC1) expression in balding scalp regions of AGA patients, suggesting involvement in cell cycle dysregulation and senescence-related processes. HDAC1-overexpressing nanovesicles were subsequently developed, characterized by high encapsulation efficiency, favorable biomimetic profiles, and cost-effective scalability. These engineered nanovesicles substantially improved cellular proliferation and migration capacities while mitigating dihydrotestosterone (DHT)-induced cytotoxicity. Transcriptomic evaluations suggested their role in promoting hair follicle regeneration via modulation of p53 and Wnt/β-Catenin signaling pathways. To address limitations in intradermal delivery, a dissolvable microneedle platform was constructed to enable

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples, often without a control group.

How we grade evidence
HumansAlopeciaHair FollicleTumor Suppressor Protein p53RegenerationAnimalsHistone Deacetylase 1Wnt Signaling PathwayExtracellular VesiclesDermis
Hair & ScalpScarHair Loss
View on PubMedDOI

Related research